Zevacor signs on as manufacturing partner for Actinium

By AuntMinnie.com staff writers

April 12, 2016 -- Immunotherapy technology developer Actinium Pharmaceuticals has tapped radiopharmaceutical developer Zevacor Pharma as a manufacturing and supply partner for its upcoming radioimmunotherapy phase III trial.

Zevacor, formerly known as IBA Molecular North America, will provide the clinical production and supply of Iomab-B, a radioimmunotherapy agent intended for use in patients older than 55 prior to their receiving a bone marrow transplant for acute myeloid leukemia (AML).

Iomab-B has received an orphan drug designation from the U.S. Food and Drug Administration (FDA), and the pivotal phase III Study of Iomab-B in Elderly Relapsed/Refractory AML (SIERRA) is expected to enroll 150 patients, according to Actinium.

Copyright © 2016 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking